Association of metabolic and inflammatory molecule levels and post-covid syndrome of varying severity
A. A. Karaseva,
A. D. Afanaseva,
E. V. Garbuzova,
E. V. Kashtanova,
Ya. V. Polonskaya,
E. M. Stakhneva,
V. S. Shramko,
L. V. Shcherbakova,
I. I. Logvinenko,
Yu. I. Ragino https://doi.org/10.20538/1682-0363-2025-2-44-51
Abstract
Aim. To study the associations of the levels of metabolic and inflammatory molecules and the severity of postCOVID syndrome (PCS) in COVID-19 convalescents.
Materials and methods. The observational cross-sectional study included 270 individuals aged 18–84 who were COVID-19 convalescents, including 191 patients with PCS of whom 97 patients had mild PCS and 94 had moderate PCS. Serum concentrations of metabolic and inflammatory molecules were determined using enzymelinked immunosorbent assay (ELISA), including: alpha interferon (IFN-α), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), insulin, C-peptide, and high-sensitivity C-reactive protein (hs-CRP).
Results. In COVID-19 convalescents with PCS of varying severity, the level of IL-6 was 1.3 times higher than in individuals without PCS. Among men with PCS, the levels of IL-6, MCP-1, and hs-CRP were 1.5, 1.2 and 1.9 times higher, respectively, compared with men without PCS. In men with moderate PCS, the level of IL-6 was 1.9 times higher and hs-CRP was 1.7 times higher than in men without PCS. The risk of having moderate PCS in COVID-19 convalescents was directly associated with the concentration of C-peptide in the blood. In men, the risk of having PCS was directly associated with the concentration of hs-CRP in the blood.
Conclusion. In COVID-19 convalescents, the risk of having moderate PCS is directly associated with the level of C-peptide in the blood. In men, the risk of having PCS is directly associated with the level of hs-CRP in the blood.
Supporting agencies: The study was carried out as part of the budget topic “Formation of Cohorts of Children, Adolescents, and Young People to Study the Mechanisms and Features of the Human Life Cycle in the Russian Population” No. FWNR-2025-0001, with the support of the scholarship of the President of the Russian Federation No. SP-2974.2022.4 and the grant of the Government of Novosibirsk region GR-24 dated June 18, 2024.
About the Authors
A. A. Karaseva
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
A. D. Afanaseva
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
E. V. Garbuzova
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
E. V. Kashtanova
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
Ya. V. Polonskaya
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
E. M. Stakhneva
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
V. S. Shramko
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
L. V. Shcherbakova
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
I. I. Logvinenko
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
Yu. I. Ragino
Research Institute of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
175/1 Boris Bogatkov St., 630089 Novosibirsk, Russian Federation
Competing Interests:
The authors declare the absence of obvious and potential conflicts of interest associated with the publication of this article.
References
1. Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of postCOVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22(4):102107. DOI: 10.1016/S1473-3099(21)00703-9
2. Sk Abd Razak R., Ismail A., Abdul Aziz A.F., Suddin L.S., Azzeri A., Sha’ari N.I. Post-COVID syndrome prevalence: a systematic review and meta-analysis. BMC Public Health. 2024;24(1):1785. DOI: 10.1186/s12889-024-19264-5.
3. Карасева А.А., Худякова А.Д., Гарбузова Е.В., Рагино Ю.И., Логвиненко И.И. Степени тяжести постковидного синдрома: систематический обзор. Архивъ внутренней медицины. 2023;13(6):422–435. DOI: 10.20514/2226-6704-2023-13-6-422-435.
4. Wang J., Jiang M., Chen X., Montaner L.J. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J. Leukoc. Biol. 2020;108(1):17–41. DOI: 10.1002/JLB.3COVR0520-272R.
5. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;(395):497–506. DOI: 10.1016/S0140-6736(20)30183-5.
6. Montefusco L., Ben Nasr M., D’Addio F., Loretelli C., Rossi A., Pastore I. et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat. Metab. 2021;(3):774–785. DOI: 10.1038/s42255-021-00407-6.
7. Schultheiß C., Willscher E., Paschold L., Gottschick C., Klee B., Henkes S.S. et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 2022;3(6):100663. DOI: 10.1016/j.xcrm.2022.100663.
8. Жданова Е.В., Рубцова Е.В., Костоломова Е.Г. Клинико-иммунологическая характеристика постковидного синдрома. Бюллетень сибирской медицины. 2024;23(2):46–54. DOI: 10.20538/1682-0363-2024-2-46-54.
9. PHOSP-COVID Collaborative Group (2022). Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet
10. Respir. Med. 2022;10(8):761–775. DOI: 10.1016/S2213-2600(22)00127-8.
11. Del Valle D.M., Kim-Schulze S., Huang H.H., Beckmann N.D., Nirenberg S., Wang B. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020;(26):1636–1643. DOI: 10.1038/s41591-020-1051-9.
12. Merad M., Blish C.A., Sallusto F., Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122–1127. DOI: 10.1126/science.abm8108.
13. Bülow Anderberg S., Luther T., Berglund M., Larsson R., Rubertsson S., Lipcsey M. et al. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine. 2021;(138):155389. DOI: 10.1016/j.cyto.2020.155389.
14. Abers M.S., Delmonte O.M., Ricotta E.E., Fintzi J., Fink D.L., Zarember K.A. et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021;6(1):e144455. DOI: 10.1172/jci.insight.144455.
15. Bechmann N., Barthel A., Schedl A., Herzig S., Varga Z., Gebhard C. et al. Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes Endocrinol. 2022;10:221–230. DOI: 10.1016/S2213-8587(21)00346-6.
16. Bunders M.J., Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity. 2020;(53):487–495. DOI: 10.1016/j.immuni.2020.08.003.
17. Varikasuvu S.R., Dutt N., Thangappazham B., Varshney S. Diabetes and COVID-19: A pooled analysis related to disease severity and mortality. Prim. Care Diabetes. 2021;15(1):24–27. DOI: 10.1016/j.pcd.2020.08.015.
18. Man D.E., Andor M., Buda V., Kundnani N.R., Duda-Seiman D.M., Craciun L.M. et al. Insulin Resistance in Long COVID-19 Syndrome. J. Pers. Med. 2024;14(9):911. DOI: 10.3390/jpm14090911.
19. Салухов В.В., Арутюнов Г.П., Тарловская Е.И., Батлук Т.И., Башкинов Р.А., Самусь И.В. и др. Влияние нарушений углеводного обмена на ранние и отдаленные клинические исходы у пациентов с COVID-19 по данным регистров АКТИВ и АКТИВ 2. Проблемы эндокринологии. 2023;69(1):36–49. DOI: 10.14341/probl13175.
20. Методические рекомендации «Особенности течения long-COVID-инфекции. Терапевтические и реабилитационные мероприятия». Терапия. 2022;1(прил.):1–147. DOI: 10.18565/therapy.2022.1suppl.1-147.
21. De Castro G.S., Gama L.R., Ramos A.F., Gatti da Silva G.,Teixeira A.A.S., Cunha-Neto E. et al. Post-COVID-19 condition: systemic inflammation and low functional exercise capacity. Front. Nutr. 2024;(11):1295026. DOI: 10.3389/fnut.2024.1295026.
22. Maamar M., Artime A., Pariente E., Fierro P., Ruiz Y., Gutiérrez S. et al. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: A cross-sectional study. Curr. Med. Res. Opin. 2022;38(6):901–909. DOI: 10.1080/03007995.2022.2042991.
Review
For citations:
Karaseva A.A., Afanaseva A.D., Garbuzova E.V., Kashtanova E.V., Polonskaya Ya.V., Stakhneva E.M., Shramko V.S., Shcherbakova L.V., Logvinenko I.I., Ragino Yu.I. Association of metabolic and inflammatory molecule levels and post-covid syndrome of varying severity. Bulletin of Siberian Medicine. 2025;24(2):44-51. (In Russ.) https://doi.org/10.20538/1682-0363-2025-2-44-51
Views:
50
Email this article 